Navigation Links
LX4211 for Diabetes Shown to Reduce Fasting and Post-Prandial Blood Sugar in Healthy Subjects
Date:9/13/2011

trointestinal-derived peptide hormone that has also been associated with reducing food intake and has been studied as an anti-obesity agent. These two gastrointestinal peptides (GLP-1 and PYY) are secreted into circulation by neuroendocrine cells (L cells) as part of a natural homeostatic mechanism that senses nutrient transit through the gastrointestinal tract. Such nutrient sensing and related mechanisms are thought to be enhanced as a result of certain types of bariatric surgery for weight loss and control of diabetes.

LX4211 treatment also produced a 50.2 mg/dL adjusted mean decrease from baseline in triglycerides, consistent with the triglyceride reduction observed in the Phase 2a study in type 2 diabetics.  In addition, LX4211, compared to placebo, produced a significant adjusted mean decrease in serum uric acid (1.52 mg/dL from baseline to last study visit, p=0.005). Serum uric acid is an emerging marker for cardiovascular risk and renal disease.  These data, together with a trend of improved blood pressure observed in the Phase 2a study, demonstrate that LX4211 has effects on multiple cardiovascular and metabolic risk factors.  Also of importance in this study was the safety of LX4211, which showed no hypoglycemia and no abdominal pain or diarrhea, consistent with the favorable safety profile associated with dual inhibition of SGLT1 and SGLT2 by LX4211 in previous clinical trials. Enrollment in Lexicon's ongoing Phase 2b study of LX4211 in patients with type 2 diabetes is on schedule, with results anticipated in the first half of 2012.

"We have now observed results from several clinical studies of LX4211 which consistently support the concept of dual SGLT1/SGLT2 inhibition for the treatment of diabetes and indicate a long-term opportunity in diabetes prevention," said Pablo Lapuerta, M.D., senior vice president of clinical development and chief medical officer. "The favorab
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
2. Phase 2 Trial of LX4211 Demonstrates Significant and Rapid Improvements in Multiple Parameters in Type 2 Diabetic Patients
3. Lexicon Presents Data Describing LX4211 Positive Phase 2 Clinical Results and Novel Mechanism of Action for Type 2 Diabetes
4. Lexicon Announces Positive Results from New Clinical Study of LX4211 in Type 2 Diabetes Patients
5. Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
6. Lexicon Presents LX4211 Clinical Data at European Association for the Study of Diabetes Annual Meeting
7. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
8. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
9. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
10. Isis Initiates Phase 1 Study of ISIS 325568 Targeting Glucagon Receptor to Treat Type 2 Diabetes
11. Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  Zafgen, Inc., a leading biopharmaceutical ... severely obese patients, today announced initial results from ... inhibitor of methionine aminopeptidase 2 (MetAP2), in patients ... genetic obesity.  These results showed improvements in body ...
(Date:1/14/2014)... InformEx, North America,s leading business partnering ... the 30 th edition of its annual conference at ... January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... and specialty chemical companies will take part in the conference, ...
(Date:1/14/2014)... Emergency Critical Care, a LifeCentre partner practice, located at 165 Fort ... first in Loudoun County to receive a ... M. Barnes , Medical Director, is a well-seasoned veterinarian of more ... , are avid scuba divers. "As altitude skiers and hikers, we ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2
... 15, 2011 Amgen (NASDAQ: AMGN ... District Court in Pennsylvania has entered final judgment ... Ltd. and Teva Pharmaceuticals USA prohibiting them from ... colony-stimulating factor) and methods for its use. Today,s ...
... key component of health care reform involves the improvement ... particularly for patients admitted to a hospital. To help ... Center for Health Quality and Innovation, which provides financial ... system. The center has now awarded nine ...
Cached Medicine Technology:Amgen Resolves G-CSF Patent Litigation With Teva 2UCLA Receives Six UC Health Quality Grants to Improve Hospital Care 2UCLA Receives Six UC Health Quality Grants to Improve Hospital Care 3UCLA Receives Six UC Health Quality Grants to Improve Hospital Care 4UCLA Receives Six UC Health Quality Grants to Improve Hospital Care 5
(Date:4/23/2014)... program could help doctors predict which patients might suffer ... , The program, which assesses brain scans using pattern ... and passport control, has been developed by researchers at ... by the Wellcome Trust, which used the software are ... , Stroke affects over 15 million people each year ...
(Date:4/23/2014)... showing the potential health benefits of probiotics, antioxidants and ... supplements. And the chemical industry is getting in on ... could deter growth, so the industry is responding with ... the cover story in Chemical & Engineering News ... Chemical Society. , Melody M. Bomgardner, a senior editor ...
(Date:4/23/2014)... Five for-profit and non-profit organizations in Washington will ... of Concept grants to accelerate maturation of promising ... Life Sciences Discovery Fund (LSDF) announced today. Also ... to the Washington Biotechnology & Biomedical Association (WBBA) ... the next generation of entrepreneurs and help early-stage ...
(Date:4/23/2014)... Midlife Occupational and Leisure Time Physical Activity on Mobility ... in midlife increases the risk of mobility limitation in ... This is found in a study which followed up ... was conducted at the Gerontology Research Center in Finland ... physical labor is often repetitive, wears the body and ...
(Date:4/23/2014)... endogenous neural precursor cells cannot alone compensate for ... perspective of neural plasticity, Dr. Yun Xiang and ... the effects of functional electrical stimulation treatment on ... basic fibroblast growth factor and epidermal growth factor ... The researchers found that functional electrical stimulation can ...
Breaking Medicine News(10 mins):Health News:Airport security-style technology could help doctors decide on stroke treatment 2Health News:Airport security-style technology could help doctors decide on stroke treatment 3Health News:LSDF announces commercialization grants and Entrepreneur Mentoring Program 2Health News:Midlife occupational and leisure-time physical activity limits mobility in old age 2
... , WASHINGTON, Sept. 18 In the ... is considered a "pre-existing condition" by many health insurers, today ... police officers, war correspondents, expectant fathers, pregnant women and patients ... denied health insurance policies. , , The ...
... various routes , FRIDAY, Sept. 18 (HealthDay News) -- ... the U.S. Food and Drug Administration can be safely ... new recommendations from the American Academy of Allergy, Asthma ... responses are weakened by medical treatments (such as for ...
... , SAN FRANCISCO, Sept. 18 Quantros(TM), ... healthcare industry, today announced a partnership with HealthWatch, Inc. - a ... Care, a national, not for profit quality improvement organization - to ... , , Quantros Patient Safety Center (QPSC(TM)), the ...
... Sept. 18 happier.com is a ... designed to help people not just be happier but "do happier. ... for users to make an immediate positive impact on ... by taking 4 validated tests with instant feedback on ...
... , Active sculptor and wood carver makes quick return ... six years of dialysis finally began to take a heavy toll on 84-year-old ... his art, and he was unable to travel, which is a major source ... patriarch to an expansive family. He,s the father of four, grandfather of five ...
... SHANGHAI, Sept. 18 /PRNewswire-Asia/ -- Avery Dennison Specialty Tape,Division, ... sector,introduced two new ultra-thin adhesives and a hydrocolloid and ... (Photo: http://www.prnasia.com/sa/2009/09/18/20090918839634.html ) , ... entire spectrum of wound care and for the most,demanding ...
Cached Medicine News:Health News:Pre-Existing Health 'Conditions' - Cops, Firefighters, Expectant Dads, and Those Suffering From Allergies, Acne and Toenail Fungus Are Uninsurable According to Internal Documents 2Health News:Swine Flu Shots Safe for People With Weak Immune Systems: Experts 2Health News:Swine Flu Shots Safe for People With Weak Immune Systems: Experts 3Health News:Quantros and HealthWatch Announce PSO Partnership 2Health News:Quantros and HealthWatch Announce PSO Partnership 3Health News:https://happier.com/form.htmhappier.com Launches a Personal Trainer for Your Happiness 2Health News:Kidney Transplant at 84, Chicago Artist Proves New Start Possible at Any Age 2Health News:Kidney Transplant at 84, Chicago Artist Proves New Start Possible at Any Age 3Health News:Kidney Transplant at 84, Chicago Artist Proves New Start Possible at Any Age 4Health News:Avery Dennison Introduces Advanced New Medical Dressing Technology at MEDTEC China 2009 2Health News:Avery Dennison Introduces Advanced New Medical Dressing Technology at MEDTEC China 2009 3
Manufacturer of the WellPro since 1992, ProGroup previously distributed the instrument through Denley and Labsystems. A direct replacement for the ProPette the WellPro performs serial dilutions in an...
... compatible with hood installations. ... system for 384-well plates, ... prepares large quantities of ... Wellpro also performs plate ...
... The Aquarius 384 is a ... Aquarius 384-well head is a unique ... washing using the included wash system. ... 250 microplate stacker system. Will ...
... new Nanopipetting System Genesis NPS based on ... allows you to miniaturize your assays for ... picking and direct dilutions., Furthermore it ... applications including gene expression analysis, gene mapping, ...
Medicine Products: